NEWS & EVENTS
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Novavax and Catalent Announce Closing of Strategic Partnership
Jul 31, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing partner for gene therapies, today announced the closing of their previously announced arrangement.
Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
Jul 16, 2019
Catalent Biologics today announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA).
Catalent’s Partner, Passage Bio, Announces New Dedicated Gene Therapy Manufacturing Suite
Jul 10, 2019
The dedicated cGMP suite is to be built under strategic partnership with Paragon Gene Therapy to support future clinical and commercial production for Passage Bio’s AAV-delivered gene therapies
Catalent’s Partner, Amicus, Announces It Has Entered Into A Strategic Partnership With Catalent For Gene Therapy Development And Manufacturing
Jul 2, 2019
The agreement supports clinical and commercial supply needs for Pompe and other lysosomal disease gene therapy programs
The Use of Continuous Chromatography in Effective Process Design to be Presented by Catalent Biologics Expert at PREP Symposium
Jul 2, 2019
Catalent today announced that Ben Kester, Manager and Senior Scientist, Purification Development, Catalent Biologics, will present at the upcoming 32nd International Symposium on Preparative and Process Chromatography (PREP Symposium).
Novavax and Catalent Biologics Enter Strategic Partnership with Acquisition of Novavax’ Manufacturing Assets and Capabilities
Jun 27, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit today announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art…
Catalent To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy
Jun 19, 2019
Bristol-Myers Squibb Company and Catalent, Inc. today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
IVERIC Bio Enters Into Strategic Manufacturing Relationship With Catalent’s Paragon Gene Therapy For Orphan Inherited Retinal Diseases
Jun 17, 2019
IVERIC bio, Inc. and Catalent Biologics, today announced that they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus vector for IVERIC bio’s gene therapy product candidates…
Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
May 23, 2019
Catalent is to launch its new OneBio SuiteSM for the integrated development, manufacturing, and clinical supply of biologic drugs at the BIO International Convention
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.